Nuveen Asset Management, LLC Nuvation Bio Inc. Transaction History

Nuveen Asset Management, LLC

$329 Billion
Q1 2024

A detailed history of Nuveen Asset Management, LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 875,362 shares of NUVB stock, worth $2.65 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

875,362

Previous 408,692 114.19%

Holding current value

$2.65 Million

Previous $617,000 416.37%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$1.46 - $3.97 $681,338 - $1.85 Million	466,670 Added 114.19%	875,362 $3.19 Million
Q4 2023 Feb 14, 2024	SELL	$0.96 - $1.53 $313,643 - $499,869	-326,712 Reduced 44.43%	408,692 $617,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $2.1 $4,997 - $8,328	-3,966 Reduced 0.54%	735,404 $985,000
Q2 2023 Aug 14, 2023	SELL	$1.56 - $1.84 $84,034 - $99,117	-53,868 Reduced 6.79%	739,370 $1.33 Million
Q1 2023 May 15, 2023	BUY	$1.6 - $2.48 $451,310 - $699,531	282,069 Added 55.18%	793,238 $1.32 Million

Q4 2022 Feb 14, 2023	SELL	$1.68 - $2.5 $107,572 - $160,077	-64,031 Reduced 11.13%	511,169 $981,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $4.04 $3,622 - $50,467	-12,492 Reduced 2.13%	575,200 $1.29 Million
Q2 2022 Aug 15, 2022	BUY	$3.24 - $5.85 $30,676 - $55,387	9,468 Added 1.64%	587,692 $1.9 Million
Q1 2022 May 16, 2022	SELL	$4.6 - $8.83 $712,471 - $1.37 Million	-154,885 Reduced 21.13%	578,224 $3.05 Million
Q4 2021 Feb 14, 2022	BUY	$7.75 - $10.05 $2.39 Million - $3.09 Million	307,748 Added 72.35%	733,109 $6.23 Million
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $1.36 Million - $1.74 Million	174,318 Added 69.44%	425,361 $4.23 Million
Q2 2021 Aug 16, 2021	BUY	$9.22 - $14.48 $2.31 Million - $3.64 Million	251,043 New	251,043 $2.34 Million

Others Institutions Holding NUVB

# of Institutions

126

Shares Held

107M

Call Options Held

40.6K

Put Options Held

2.9K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $658M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Nuvation Bio Inc. Transaction History